Novo nordisk share price

The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas.

Research shows urgent need for policies to encourage weight loss and cut disease risk. The EU is missing out on trillions of euros of capital for its businesses. German pharma group finds no unexpected side effects during trial, including at higher doses. Financial Times Close. Search the FT Search. Show more World link World.

Novo nordisk share price

In order to secure liquidity for both the Novo Nordisk B shares and American Depositary Receipts ADRs and bring price levels in line with market practice for especially the ADRs, the Board of Directors has decided to split the trading units in a two-for-one ratio. After the split, the total number of A shares of nom. DKK 0. Each A-share of nom. DKK 0,10 carries votes. Consequently, the total number of votes relating to the A shares is ,,, votes. After the split, the total number of B shares of nom. Each B-share of nom. DKK 0,10 carries 10 votes. Consequently, the total number of votes relating to the B shares is 34,,, votes. Please find the company announcement regarding the stock split here. Barclays Capital Emily Field, emily. Berenberg Kerry Holford, kerry.

Can I write off my loss? German pharma group finds no unexpected side effects during trial, including at higher doses.

.

This means our website may not look and work as you would expect. Read more about browsers and how to update them here. Invest now. To buy shares in , you'll need to have an account. Explore the options. The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation. You are here:. Sell: Market closed Prices as at close on 8 March Switch to live prices.

Novo nordisk share price

Novo Nordisk, of anti-obesity drug Wegovy fame, reveals encouraging initial trial data for new weight loss drug that could potentially overtake Wegovy. Pharmaceutical giant Novo Nordisk has recently overtaken electric vehicle maker Tesla, in terms of market valuation, following upbeat initial trial data for a new obesity drug. Following the launch of Wegovy in June , Novo Nordisk has established itself as a leader in the weight-loss drug sector, making the news of a potential new drug even more highly anticipated.

Bosch 20w40 engine oil

Add Tickers. Customize MarketWatch Have Watchlists? Stifel Eric Le Berrigaud, eric. Symbols Loading Open NVO U. Berenberg Kerry Holford, kerry. Why More Are Coming. Can I write off my loss? Pfizer Inc. Liberum Graham Doyle, graham. They Could Keep Climbing. Consequently, the total number of votes relating to the A shares is ,,, votes. All markets data located on FT.

Key events shows relevant news articles on days with large price movements. Eli Lilly And Co. LLY 2.

Intron Health Naresh Chouhan, naresh intronhealthresearch. Access Premium Tools. Show more Markets link Markets. Add to Your Portfolio New portfolio. This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk Feb. Short selling activity Low. Chrome Safari Firefox Edge. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. Add Tickers. They Could Keep Climbing.